References
- E S Jaffe, Harris, N L, Stein, H, Vardiman, J W. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. LyonFrance, IARC Press. 2001
- Merlat A, Lai J L, Sterkers Y, Demory J L, Bauters F, Preudhomme C, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999; 13: 250–257
- Van der Holt B, Breems D A, Berna Beverloo H, van den Berg E, Burnett A K, Sonneveld P, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007; 136: 96–105
- Soenen V, Preudhomme C, Roumier C, Daudignon A, Laï J L, Fenaux P. 17 p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91: 1008–1015
- Wojcik I, Szybka M, Golanska E, Rieske P, Blonski J Z, Robak T, et al. Abnormalities of the P53, MDM2, BCL2, and BAX genes in acute leukemia. Neoplasma 2005; 52: 318–324
- Eischen C M, Weber J D, Roussel M F, Sherr C J, Cleveland J L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658–2669
- Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
- Nahi H, Lehmann S, Bengtzen S, Jansson M, Möllgård L, Paul C, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma 2008; 49: 508–516
- Kojima K, Konopleva M, Samudio I J, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150–3159